The factor VII activating protease G511E (Marburg) variant and cardiovascular risk
Helen Ireland(1), George J. Miller(2), Karen E.Webb(1), Jackie A. Cooper(1), Steve E. Humphries(1)
(1)Division of Cardiovascular Genetics, Department of Medicine, British Heart Foundation Laboratories, Royal Free and University College Medical School, London, UK (2)Medical Research Council Cardiovascular Group, Department of Environmental and Pre
A previous study had shown a strong relationship between a
variant in factor VII activating protease (FSAP G511E) and
advanced carotid atheroma. In-vitro, the variant has reduced
fibrinolytic but normal pro-coagulant activity, which may constitute
a prothrombotic state. The current study has addressed
risk for coronary heart disease in a prospective study of cardio
vascular disorders (Northwick Park Heart Study II). An interactive
effect upon risk was found between the 511E allele and
elevated levels of cholesterol and triglyceride. Fibrinogen could
substitute for triglyceride levels in this risk-interaction analysis.
The findings support the proposal that the FSAP 511E allele
exacerbates atherosclerosis or its clinical sequelae.